Research Article

Molecular Modeling Studies of Thiophenyl C-Aryl Glucoside SGLT2 Inhibitors as Potential Antidiabetic Agents

Mukesh C. Sharma¹ and Smita Sharma²

¹School of Pharmacy, Devi Ahilya University, Takshila Campus, Khandwa Road, Indore 452 001, India
²Department of Chemistry, Chodhary Dilip Singh Kanya Mahavidyalaya, Bhind 477001, India

Correspondence should be addressed to Mukesh C. Sharma; mukesh2206@rediffmail.com

Received 14 May 2014; Revised 29 October 2014; Accepted 29 October 2014; Published 10 December 2014

A QSAR study on thiophenyl derivatives as SGLT2 inhibitors as potential antidiabetic agents was performed with thirty-three compounds. Comparison of the obtained results indicated the superiority of the genetic algorithm over the simulated annealing and stepwise forward-backward variable method for feature selection. The best 2D QSAR model showed satisfactory statistical parameters for the data set ($r^2 = 0.8499$, $q^2 = 0.8267$, and pred.$r^2 = 0.7729$) with four descriptors describing the nature of substituent groups and the environment of the substitution site. Evaluation of the model implied that electron-rich substitution position improves the inhibitory activity. The good predictive 3D-QSAR models by k-nearest neighbor (kNN) method for molecular field analysis (MFA) have cross-validated coefficient $q^2$ value of 0.7663 and predicted $r^2$ value of 0.7386. The results have showed that thiophenyl groups are necessary for activity and halogen, bulky, and less bulky groups in thiophenyl nucleus enhanced the biological activity. These studies are promising for the development of novel SGLT2 inhibitor, which may have potent antidiabetic activity.

1. Introduction

One of the main features of diabetes is the elevation of blood sugar with its deleterious consequences in a variety of tissues [1]. Thus, control of the plasma glucose level is of utmost importance in the treatment of this disease. In recent years, the idea that affecting glucose absorption in the intestine and/or the glucose reabsorption in the kidney might be a possible way to control the sugar level has evolved. Diabetes comprises a group of metabolic disorders characterised by chronic hyperglycaemia with disorders in the metabolism of carbohydrate, fat, and protein that result in defects in secretion and action of insulin [2]. Dysfunction and failure of various organs, especially the eyes, kidneys, nerves, and heart, and the blood vessels are the usual complications of diabetes [3, 4]. Diabetes is mainly divided into four main types including insulin-dependent diabetes mellitus (type 1), non-insulin-dependent diabetes mellitus (type 2), gestational diabetes, and other specific types [5]. Diabetes mellitus type 2 (T2DM) accounts for almost 90% of diabetes cases, with the property of insulin resistance and beta-cell dysfunction that induces hyperglycemia [6]. Medical complications associated with T2DM include cardiovascular disease, stroke, nephropathy, retinopathy, renal failure, and amputations of the extremities [7]. In recent years, much attention has been given to sodium-dependent glucose cotransporters (SGLTs), mediators of reabsorption of glucose in the human body. Sodium-dependent glucose cotransporter 2 (SGLT2) is a high-capacity, low-affinity transporter expressed selectively in the S1 domain of the proximal tubule in the kidney and is responsible for 90% of renal glucose reuptake. Sodium dependent glucose cotransporter 1 (SGLT1), on the other hand, is a low-capacity, high-affinity transporter distributed in the kidney, gut, and other tissues, responsible for the remaining 10% of glucose reuptake [8]. $\text{Na}^+$-glucose cotransporter (SGLT) is a membrane protein that plays an important role in the reabsorption of glucose in the kidneys. Sodium-dependent glucose cotransporters (SGLTs), mediators of reabsorption of glucose in the kidney, have recently emerged as novel drug targets for the treatment of diabetes [9]. SGLT is known to have three isoforms (SGLT1, SGLT2, and SGLT3) [10–12]. SGLT1 is expressed primarily
in the brush border membrane of mature enterocytes in the small intestine, where it absorbs dietary glucose and galactose from the gut lumen [13]. SGLT2, expressed exclusively in the kidney, is located in the S1 segment of the proximal convoluted tubule of the kidney. It is a low-affinity, high-capacity cotransporter and is responsible for 90% of renal glucose reabsorption [14]. Several therapeutic agents are available for monotherapy or for combination therapy with different mechanisms to treat diabetics, such as metformin, rosiglitazone, sitagliptin, acarbose, and glimepiride [15]. The obvious need for new approaches to treat patients with uncontrolled T2DM has prompted continuous exploration of alternative targets involved in maintenance of glucose homeostasis. Several SGLT2 inhibitors have been reported as undergoing clinical trials. Phlorizin [16], 3-(benzo[b]furan-5-yl)-2′,6′-dihydroxy-4′-methylpropio phenone-2′-O-β-D-glucopyranoside [17], sergliflozin [18], and remogliflozin [19] are O-glycosides and show strong inhibition of SGLT2. They also demonstrate efficacy in vivo when administered orally in rats or mice. They induce a glucosuric response, the result of the blockade of renal glucose reabsorption, and consequently lead to reduction of the blood glucose level and improvement of insulin sensitivity [20]. Quantitative structure-activity relationship (QSAR) studies can be utilized to predict eye irritation potential as an alternative in silico method, just as it has been used successfully to predict several other toxicological endpoints for some time [21]. Hence, in continuation to our efforts [22–67] in developing QSAR studies for angiotensin II AT1 receptor, antitubercular agents, antimalarial activity, antimicrobial activity, antibacterial activity, COX inhibitors, and so forth.

In this study, we have taken thiophenyl derivatives for performing 2D and 3D quantitative structural-activity relationship analysis and calculations in order to understand their stereoelectronic properties. Genetic algorithm (GA), simulated annealing (SA), and stepwise forward-backward variable selection methods have been employed for selection of relevant descriptors. The obtained results provide further insight into some beneficial information in structural modifications to design new potential SGLT2 inhibitors. Moreover, new compounds with high predictive activities were designed.

2. Materials and Methods

2.1. Data Set. The biological data set was chosen from a series of thirty-three thiophenyl derivatives as SGLT2 inhibitors as potential antidiabetic agents reported by Lee et al. [68]. The biological activity values [IC50 (nM)] reported in nanomolar units were converted to their molar units pIC50 and subsequently used as the dependent variable for the QSAR analysis. The converted to pIC50 for the QSAR analysis along with the structure of the compounds in the series are listed in Table 1 (marked with asterisk). The test compounds were selected manually such that the structural diversity and wide range of activity in the data set were included. In this paper, a series of thiophenyl compounds with substitutions at X and R position of thiophenyl moiety are subjected to examining the relationships between structural modifications and activities against hSGLT2 inhibitors with the help of QSAR modeling.

2.2. Computational Details. All the computational studies were performed by V-life MDS (Molecular Design Suite) 3.5 software supplied by V-life Sciences Technologies Pvt. Ltd., Pune, India [69]. The sketched structures were used for the calculation of 2D molecular descriptors using QSAR module of Molecular Design Suite software. Each compound was subjected to energy minimization and batch optimization using Merck Molecular Force Field (MMFF), fixing Root Mean Square Gradients (RMS) to 0.01 kcal/mol Å [70].

The sphere exclusion method [71] was adopted total set of inhibitors was divided randomly into a training set (26 compounds) for generation of QSAR models and a test set (7 compounds) for validation of the developed model. This random division of data set will be done through several cycles in order to get the best QSAR model. This study will help in rational drug designing of these derivatives as SGLT2 inhibitors for the eradication of T2DM. The unicolom statistics of the training and test sets are reported in Table 2. The maximum and minimum value in training and test set were compared in a way that

1. the maximum value of pIC50 of test set should be less than or equal to maximum value of pIC50 of training set,
2. the minimum value of pIC50 of test set should be higher than or equal to minimum value of pIC50 of training set.

2.3. Calculating 2D Descriptors. In the current approach, an attempt has been taken to understand the structural and physicochemical requirements of a set of hSGLT2 inhibitors by the help of regression 2D quantitative structure-activity relationship (2D QSAR). The energy-minimized geometry was used for the calculation of the various 2D descriptors such as topological, shape and geometrical, and physicochemical parameters such as individual (H-Acceptor count, H-Donor count, XlogP, retention index (Chi), element count, estate numbers, estate contribution, and alignment-independent descriptors were used as predictor variables), as they were found to be appropriate for the development of models. A considerable number of the 265 physicochemical parameters, 300 alignment type parameters, and 99 atoms types count descriptors calculations were done using the V-life, MDS 3.5. The preprocessing of the independent variables (i.e., 2D descriptors) was done by removing the invariable (constant column) which resulted in a total of 216 molecular descriptors to be used for QSAR analysis. The various alignment-independent descriptors were also calculated. In this study to calculate A1 descriptors, we have used the following attributes: 2 (double bonded atom), 3 (triple bonded atom), C, N, O, S, H, F, Cl, Br, and I, and the distance range of 0–7. The QSAR models were built with the consideration of the applicability of the descriptor for the activity. Various types of physicochemical descriptors have been calculated which are shown in the data sheet (Table 3).
Table 1: Structure and biological activity of thiophenyl derivatives hSGLT2 inhibitors.

| S. number | X | R       | IC₅₀  | pIC₅₀  |
|-----------|---|---------|-------|--------|
| 1         | Cl| ![Structure 1](image1) Me | 86.5  | 7.0629 |
| 2         | Cl| ![Structure 2](image2) Et | 34.6  | 7.4609 |
| 3*        | Cl| ![Structure 3](image3) OH | 140   | 6.8538 |
| 4         | Cl| ![Structure 4](image4) | 65.0  | 7.1870 |
| 5         | Cl| ![Structure 5](image5) | 54.6  | 7.2628 |
| 6*        | Cl| ![Structure 6](image6) | 111   | 6.9546 |
| 7         | Cl| ![Structure 7](image7) | 94    | 7.0268 |
| 8         | Cl| ![Structure 8](image8) | 115   | 6.9393 |
| S. number | X | R | IC<sub>50</sub> | pIC<sub>50</sub> |
|-----------|---|---|----------------|-----------------|
| 9         | Cl |   | 70.7          | 7.1505          |
| 10*       | Cl |   | 12.8          | 7.8927          |
| 11        | Cl |   | 48.4          | 7.3151          |
| 12        | Cl |   | 11.9          | 7.9244          |
| 13        | Cl |   | 57.2          | 7.2426          |
| 14*       | Cl |   | 162           | 6.7904          |
| 15        | Cl |   | 60.2          | 7.2204          |
| 16        | Cl |   | 4.47          | 8.3496          |
Table 1: Continued.

| S. number | X  | R                  | IC<sub>50</sub> | pIC<sub>50</sub> |
|-----------|----|--------------------|-----------------|-----------------|
| 17        | Cl | ![Structure](image) | 10.3            | 7.9871          |
| 18        | Cl | ![Structure](image) | 91.3            | 7.0395          |
| 19<sup>*</sup> | H  | ![Structure](image) | 11.5            | 7.9393          |
| 20        | H  | ![Structure](image) | 8.73            | 8.0589          |
| 21        | H  | ![Structure](image) | 50.2            | 7.2992          |
| 22<sup>*</sup> | H  | ![Structure](image) | 27.5            | 7.5606          |
| 23        | H  | ![Structure](image) | 21.1            | 7.6757          |
| 24        | H  | ![Structure](image) | 71.4            | 7.1463          |
Table 1: Continued.

| S. number | X  | R  | IC<sub>50</sub> | pIC<sub>50</sub> |
|-----------|----|----|----------------|-----------------|
| 25<sup>*</sup> | H  | OMe| 68.9           | 7.1617          |
| 26        | H  | Cl | 451            | 6.3458          |
| 27        | H  | t-Bu| 88.3           | 7.0540          |
| 28        | H  |   | 69.6           | 7.1573          |
| 29<sup>*</sup> | H  |   | 24.8           | 7.6055          |
| 30        | H  |   | 59.8           | 7.2232          |
| 31        | Br |   | 12.4           | 7.9065          |
| 32        | OMe|   | 49.5           | 7.3053          |
Table 1: Continued.

| S. number | X  | R        | IC\(_{50}\) | pIC\(_{50}\) |
|-----------|----|----------|-------------|-------------|
| 33\(^*\) | Me |          | 29.3        | 7.5331      |

\(^*\) Structures with (*) are included in test set validation.

Table 2: Unicolumn statistics of training and test set for 2D QSAR studies.

| Data set | Average | Max    | Min    | Std. dev. | Sum       |
|----------|---------|--------|--------|-----------|-----------|
|          |         |        |        |           | 2D QSAR   |
| Training | 1.6127  | 2.6542 | 0.6503 | 0.4426    | 41.9299   |
| Test     | 1.7765  | 2.2095 | 1.1072 | 0.3889    | 12.4355   |
|          |         |        |        |           | 3D QSAR   |
| Training | 1.5401  | 2.2095 | 0.6503 | 0.4163    | 36.9636   |
| Test     | 1.9335  | 2.6542 | 1.3945 | 0.3452    | 17.4018   |

2.4. Calculating 3D Descriptors. Energy minimized and geometry optimized structures of molecules were aligned by the template-based method [72] where a template structure is defined and used as a basis for alignment of a set of molecules, and a reference molecule is chosen on which the other molecules of the data set get aligned considering the chosen template. In the present study, we aligned the database by fitting all of the compounds on most active compound 16 (Figure 1(a)) as an alignment template using a common substructure with the V-life MDS routine database alignment. The superimposition of all molecules based on minimizing root mean square deviation (RMSD) is shown in Figure 1(b).

The steric, electrostatic, and hydrophobic fields were calculated at each lattice intersection of a regularly spaced grid of 2.0 Å. Methyl probe of charge +1 with 10.0 kcal/mole electrostatic and 30.0 kcal/mole steric and hydrophobic cutoff was used for fields generation. This resulted in calculation of 4500 field descriptors (1500 for each steric, electrostatic, and hydrophobic which theoretically form a continuum) for all the compounds in separate columns (Table 3).

2.5. External Validation for 2D QSAR Models. The QSAR models were assessed by the number of cross-validated \( R^2 \) by leave-one-out method [73] (\( q^2 \)), cross-validated standard error (\( q^2_{\text{se}} \)), predicted \( R^2 \) for external test set (pred\( r^2 \)), and standard error for predicted \( R^2 \) (pred\( r^2_{\text{se}} \)). The internal cross-validated predictability (\( q^2 \)) was evaluated by the equation given below:

\[
q^2 = 1 - \frac{\sum (y_i - \hat{y}_i)^2}{\sum (y_i - y_{\text{mean}})^2},
\]

where \( y_i, \hat{y}_i \) are the actual and predicted activity of the \( i \)th molecule in the training set, respectively, and \( y_{\text{mean}} \) is the average activity of all molecules in the training set. For external validation, activity of each molecule in the test set was predicted using the model generated from the training set. The pred\( r^2 \) value is calculated as follows:

\[
\text{Pred.} r^2 = 1 - \frac{\sum (y_i - \hat{y}_i)^2}{\sum (y_i - y_{\text{mean}})^2},
\]

where \( y_i, \hat{y}_i \) are the actual and predicted activity of the \( i \)th molecule in the test set, respectively, and \( y_{\text{mean}} \) is the average activity of all molecules in the training set. Both summations are over all molecules in the test set. Thus, the pred\( r^2 \) value is indicative of the predictive power of the current model based on the external test set.

2.6. Evaluation of the Quantitative of Models. Among several search algorithms, stepwise (SW) forward variable selection
Table 3: Selected descriptors values for QSAR models.

| $\text{SsCH}_3\text{count}$ | $T\_C\_Cl_1$ | $S\_1044$ | $E\_184$ | $E\_1139$ | $H\_1153$ |
|-----------------------------|--------------|----------|--------|--------|--------|
| 13.35725                   | 1            | -0.00234 | -0.00103 | 0.070427 | 0.068996 |
| 14.89175                   | 1            | -0.00252 | -0.03374 | 0.039663 | 0.110293 |
| 13.05024                   | 1            | -0.00332 | -0.0034  | 0.045418 | 0.156499 |
| 12.66982                   | 1            | -0.00271 | -0.07924 | 0.015991 | 0.205079 |
| 13.19176                   | 1            | -0.00718 | -0.05341 | 0.01499  | 0.156726 |
| 13.4038                    | 1            | -0.00276 | -0.02181 | 0.126288 | 0.213233 |
| 13.05024                   | 1            | -0.00272 | -0.11568 | 0.049628 | 0.170716 |
| 14.11489                   | 1            | -0.00229 | -0.04659 | 0.03041  | 0.190254 |
| 13.19176                   | 1            | -0.0037  | -0.05161 | 0.007637 | 0.195659 |
| 13.85076                   | 1            | -0.00269 | -0.09992 | 0.148325 | 0.170358 |
| 13.95209                   | 1            | -0.002   | -0.05398 | 0.046206 | 0.178527 |
| 13.49164                   | 1            | -0.00307 | -0.04381 | 0.022364 | 0.196138 |
| 13.8452                    | 1            | -0.00213 | -0.03588 | 0.01794  | 0.135694 |
| 13.11122                   | 1            | -0.00219 | -0.05675 | 0.025435 | 0.117383 |
| 11.57052                   | 1            | -0.0077  | -0.03111 | 0.040108 | 0.13964  |
| 13.05024                   | 1            | -0.00148 | -0.06435 | 0.079842 | 0.242054 |
| 13.05024                   | 1            | -0.00131 | -0.03439 | 0.040536 | 0.219392 |
| 12.37104                   | 1            | -0.00205 | -0.00201 | 0.013029 | 0.200942 |
| 13.85076                   | 0            | -0.00288 | -0.02182 | 0.060327 | 0.072212 |
| 13.49164                   | 0            | -0.00392 | -0.07865 | 0.052315 | 0.116761 |
| 11.65703                   | 0            | -0.00194 | -0.0367  | 0.068249 | 0.151754 |
| 12.45755                   | 1            | -0.00638 | -0.03708 | 0.025638 | 0.202708 |
| 13.35725                   | 0            | -0.00325 | -0.00005 | 0.016382 | 0.181212 |
| 12.3107                    | 0            | -0.00272 | -0.06519 | 0.139852 | 0.220012 |
| 13.11122                   | 0            | -0.00186 | -0.04364 | 0.073036 | 0.168351 |
| 12.30098                   | 0            | -0.00406 | -0.01576 | 0.034676 | 0.18917  |
| 13.1015                    | 1            | -0.00226 | -0.03521 | 0.000739 | 0.211024 |
| 11.56143                   | 1            | -0.00212 | -0.07403 | 0.159932 | 0.171132 |
| 12.11965                   | 1            | -0.00331 | -0.02547 | 0.047064 | 0.188637 |
| 12.3107                    | 1            | -0.00178 | -0.03979 | 0.004465 | 0.186037 |
| 12.92017                   | 1            | -0.0024  | -0.03588 | 0.030881 | 0.137912 |
| 13.11122                   | 1            | -0.00145 | -0.05675 | 0.032062 | 0.126376 |
| 13.35725                   | 1            | -0.00109 | -0.00103 | 0.070427 | 0.137455 |
| 14.89175                   | 1            | -0.0011  | -0.03374 | 0.039663 | 0.232216 |
| 13.05024                   | 1            | -0.00082 | -0.0034  | 0.045418 | 0.257901 |
| 12.66982                   | 1            | -0.00144 | -0.07924 | 0.015991 | 0.22212 |
| 13.19176                   | 1            | -0.00178 | -0.05341 | 0.01499  | 0.144703 |
| 13.4038                    | 1            | -0.00071 | -0.02181 | 0.126288 | 0.132103 |
| 13.05024                   | 1            | -0.00234 | -0.11568 | 0.049628 | 0.068996 |
| 14.11489                   | 1            | -0.00252 | -0.04659 | 0.03041  | 0.110293 |
| 13.19176                   | 1            | -0.00332 | -0.05161 | 0.007637 | 0.156499 |

method, genetic algorithms (GA), and simulated annealing (SA) based feature selection procedures are most popular for building QSAR models and can explain the situation more effectively. The models were also subjected to the test for criteria of external validation as suggested by Golbraikh and Tropsha [71]. To know predictive potential of the models, squared correlation coefficient values between the observed and predicted values of the test set compounds with intercept ($r^2$) were calculated. Interchange of the axes gives the value of $r^2$. According to Golbraikh and Tropsha, models are considered acceptable, if they satisfy all of the following conditions:

1. $Q^2 > 0.5$,
2. $r^2 > 0.6$.

When the observed values of the test set compounds (y-axis) are plotted against the predicted values of the
Figure 1: (a) Thiophenyl ring (template structure). (b) Alignment of thiophenyl derivatives. (c) Contribution charts of the descriptors for the 2D QSAR model-1. (d) Plot of observed versus predicted activity by 2D QSAR model-1. (e) Contribution plot for steric and electrostatic interactions GA-PLS model. (f) Plot of observed versus predicted activity by 3D QSAR GA-PLS model. (g) Contribution plot for steric and electrostatic interactions SA-PLS model. (h) Plot of observed versus predicted activity by 3D QSAR SA-PLS model. (i) Contribution plot for steric, hydrophobic, and electrostatic interactions SW-PLS model. (j) Plot of observed versus predicted activity by 3D QSAR SW-PLS model.
3. Results and Discussion

QSAR study was performed on thiophenyl C-aryl glucoside derivatives for their SGLT2 inhibitors as potential antidiabetic agents. Comparison of the obtained results indicated the superiority of the genetic algorithm over the simulated annealing (SA) and stepwise forward-backward variable method for feature selection:

\[ pIC_{50} = 0.6451 \pm 0.1584 \text{ ScH}_2 \text{count } + 0.4287 
\pm 0.0851 \text{ } T_{C-Cl} \text{L } - 0.2574 \pm 0.0036 \text{ LUMO energy} 
+ 0.2789 \pm 0.0487 \text{ SaaSE-index}; \]

\[ N_{\text{training}} = 26, \ N_{\text{test}} = 7, \ \text{degree of freedom } = 21, \ r^2 = 0.8499, \ q^2 = 0.8267, \ F-\text{test } = 45.8975, \ r^2_{\text{se}} = 0.3098, \]

\[ q^2_{\text{se}} = 0.3464, \ \text{pred}_{r^2} = 0.7729, \ \text{and } \text{pred}_{r^2_{\text{se}}} = 0.6158. \]

The significant model with \( r^2 = 0.8499 \) was considered, as model-1 showed an internal predictive power (\( q^2 = 0.8267 \)) and a predictivity for the external test set (\( \text{pred}_{r^2} = 0.7729 \)) of about 77%. The \( F-\text{test } = 45.897 \) shows the statistical significance of 99.9% of the model which means that the probability of failure of the model is 1 in 10000. In addition, the randomization test shows confidence of ~99.9% that the generated model is not random and hence it is chosen as the QSAR model. Genetic algorithm-PLS model indicates the positive contribution of ScH\(_2\) count, and SaaSE-index showed that increase in the values of these descriptors is beneficial for the SGLT2 inhibitors. From the above model, it is clear that the descriptor \( T_{C-Cl} \text{L } \) contributes positively to the SGLT2 inhibitors activity, which corresponds to count of number of carbon atoms separated from any chlorine atom by 1-bond distance. Thus, the presence of chlorine substituents (like in compounds 1-18) would increase the activity. Descriptor ScH\(_2\) count indicates that increase in methyl group of R position may lead to an increase in the activity. Its positive value suggests that increasing the number of such carbons will lead to better SGLT2 inhibitors. This suggests that substituents such as methyl would increase the activity. The above results are in close agreement with the experimental observations, where compounds 10, 15, 16, 17, and 28–33 at the R position produce SGLT2 inhibitors. Molecules with negative coefficient LUMO energy can accept electrons more easily than those having high LUMO energy. The SaaSE-index (~24%) shows the sulphur atom connected with two aromatic bonds in the molecule and is inversely proportional to the activity. This further suggests that the increase in electronnegative atom environment adjacent to indicated sulphur atom would result in increase in the activity. In addition, in agreement with QSAR model, presence of more bulky and hydrophilic substituents like methoxy at ring \( R \) led to an increase in SGLT2 potency. On the other hand, more lipophilic halogens like chloro in this \( X \) position retain the SGLT2 inhibition activities. The residuals (observed-predicted activity) were found to be minimal and are presented in Table 4. The statistical results of best model and the correlation matrix between the physicochemical parameters and the biological activity for model-1 are presented in Table 5. The contribution chart of selected descriptors is represented in Figure 1(c). Also, the graph for observed versus predicted activity for the series is plotted in Figure 1(d) which shows good correlation.

Molecular fields are the steric, electrostatic, and hydrophobic interaction energies which are used to develop a model for 3D QSAR. In this study, 3D QSAR models were generated by kNN-MFA in conjunction with genetic algorithms (GA), simulated annealing (SA), and stepwise (SW) forward-backward selection methods:

\[ pIC_{50} = S_{1044} (-0.0317, -0.0317) - E_{184} (-0.2885, -0.2885) - S_{931} (-0.0306, -0.0306); \]

\[ N_{\text{training}} = 26, \ N_{\text{test}} = 7, \ q^2 = 0.7663, \ q^2_{\text{se}} = 0.3389, \]

\[ F-\text{test } = 38.4683, \ \text{and } \text{pred}_{r^2} = 0.7386. \]

The steric and electrostatic interaction energies are computed at the lattice points of the grid using a methyl probe of charge +1. The best GA-kNN MFA 3D QSAR model that has a \( q^2 \) of 0.7663 and \( \text{pred}_{r^2} \) of 0.7386 was considered. The points generated in GA-kNN MFA 3D QSAR model are \( S_{1044} (-0.0317, -0.0317), E_{184} (-0.2885, -0.2885), \) and \( S_{931} (-0.0306, -0.0306). \) Figure 1(e) shows the contribution plot of the three models for the electrostatic and steric fields, respectively, and indicates relative regions of the local fields around the aligned molecules leading to activity variation in the model. For electrostatic field and steric fields, the lattice points generated in the model are \( E_{184} (-0.2885, -0.2885) \) and \( S_{1044} (-0.0317, -0.0317) \) and \( S_{931} (-0.0306, -0.0306). \) These points suggested the significance of electrostatic properties as indicated in the ranges in parentheses for maximum SGLT2 inhibitory activity. The negative value for \( E_{184} \) means that electron-withdrawing substituents in this region are favorable and would increase SGLT2 inhibitory activity, as shown by the presence of chlorine group in the active compounds. Therefore, less steric and more steric substituents were preferred at the position of generated data points \( S_{1044} \) and \( S_{931}, \) respectively, for enhancing the biological activity of thiophenyl pharmacophore. Two data points generated at the position of \( R \) around thiophenyl nucleus were steric points \( S_{1044} \) and \( S_{931}, \) which indicates that less steric or less bulky substituents are favorable on this site. On the other hand, less electronreagative groups such as hydroxyl and nitro. The electrostatic blue ball model around \( R \) positions of the thiophenyl suggested the electron-withdrawing groups on this position benefited potency; this may be the reason why compounds with double bonds at \( R \) positions had higher potencies than other compounds. In addition, a red contour near the position suggested the electron-withdrawing substituent would increase the activity. Therefore, the –OH at \( R \) position resulted in significant increased activity. Electron-withdrawing nature of the electronnegative chloro atom does contribute to the SGLT2 inhibitory activity of the molecule. The graph for observed versus predicted activity for the series is plotted in Figure 1(f) which shows good correlation.
Table 4: Comparative observed and predicted activities (LOO) of thiophenyl SGLT2 inhibitors.

| Com | pIC$_{50}$ | 2D model-1 | 3D model-GA-PLS | 3D model-SA-PLS | 3D model-SW-PLS |
|-----|------------|------------|-----------------|-----------------|-----------------|
|     | Pred. Res. | Pred. Res. | Pred. Res.      | Pred. Res.      | Pred. Res.      |
| 1   | 7.0629     | 7.1845     | -0.1216         | 7.1847          | -0.1218         |
| 2   | 7.4609     | 7.4978     | -0.0369         | 7.3679          | 0.093           |
| 3   | 6.8538     | 6.8737     | -0.0199         | 6.7565          | 0.0973          |
| 4   | 7.187      | 7.2319     | -0.0449         | 7.0789          | 0.1081          |
| 5   | 7.2628     | 7.2564     | 0.0064          | 7.4543          | -0.1915         |
| 6   | 6.9546     | 6.9448     | 0.0098          | 6.9121          | 0.0425          |
| 7   | 7.0268     | 7.1464     | -0.1196         | 7.0723          | -0.0455         |
| 8   | 6.9393     | 6.8185     | -0.0422         | 6.9644          | -0.0251         |
| 9   | 7.1505     | 7.1854     | -0.0349         | 7.0746          | 0.0759          |
| 10  | 7.8927     | 7.8289     | 0.0638          | 7.8694          | 0.0233          |
| 11  | 7.3151     | 7.3283     | -0.0132         | 7.3729          | -0.0578         |
| 12  | 7.9244     | 7.9135     | 0.0109          | 7.9918          | -0.0674         |
| 13  | 7.2426     | 7.2857     | -0.0431         | 7.2498          | -0.0072         |
| 14  | 6.7904     | 6.7845     | 0.0059          | 6.7954          | -0.005          |
| 15  | 7.2206     | 7.2138     | 0.0066          | 7.2525          | -0.0321         |
| 16  | 8.3496     | 8.3791     | -0.0295         | 8.3875          | -0.0379         |
| 17  | 7.9871     | 7.9845     | 0.0026          | 7.9949          | -0.0078         |
| 18  | 7.0395     | 7.1278     | -0.0883         | 7.1392          | -0.0997         |
| 19  | 7.9393     | 7.9243     | 0.015           | 7.9418          | -0.0025         |
| 20  | 8.0589     | 7.9275     | 0.1314          | 8.0692          | -0.0103         |
| 21  | 7.2992     | 7.2961     | 0.0031          | 7.1491          | 0.1501          |
| 22  | 7.5606     | 7.5884     | -0.0278         | 7.4281          | 0.1325          |
| 23  | 7.6757     | 7.6978     | -0.0221         | 7.5946          | 0.0811          |
| 24  | 7.1463     | 7.1326     | 0.0137          | 7.1384          | 0.0079          |
| 25  | 7.1617     | 7.0968     | 0.0649          | 7.1948          | -0.0331         |
| 26  | 6.3458     | 6.3291     | 0.0167          | 6.3259          | 0.0199          |
| 27  | 7.054      | 7.1853     | -0.1313         | 6.9342          | 0.198           |
| 28  | 7.1573     | 7.2218     | -0.0645         | 7.0202          | 0.1371          |
| 29  | 7.6055     | 7.6283     | -0.0228         | 7.6163          | -0.0108         |
| 30  | 7.2232     | 7.2346     | -0.0114         | 7.2458          | -0.0226         |
| 31  | 7.9065     | 7.8579     | 0.0486          | 7.8881          | 0.0184          |
| 32  | 7.3053     | 7.2982     | 0.0071          | 7.0424          | 0.2629          |
| 33  | 7.5331     | 7.4728     | 0.0603          | 7.3466          | 0.1865          |

The residuals (observed-predicted activity) were found to be minimal and are presented in Table 4:

$$N_{training} = 26, N_{test} = 7, q^2 = 0.7254, q^2_{sec} = 0.3795, F_{test} = 31.8965, \text{and pred. } r^2 = 0.6938.$$ 

3D data points generated, which contribute to SA kNN-MFA QSAR model, are shown in Figure 1(g). The external predictability of the above 3D QSAR model using the test set was determined by Pred. $r^2$, which is 0.6938. The points generated in SA kNN-MFA 3D QSAR model are $E_{1139}$ (0.1545, 0.1545) and $S_{2586}$ ($-0.3001$, $-0.3001$), that is, electrostatic and steric interaction fields at lattice points 1139 and 646, respectively. Positive values for $E_{1139}$ show that electron-donating groups on the thiophenyl ring increase biological activity of compounds. On the other hand, thiophenyl ring might be substituted with either electron-withdrawing or
electron-donating groups without loss of activity. 3D QSAR studies showed requirement of steric group at R position. The graph for observed versus predicted activity for the series is plotted in Figure 1(h). The residuals (observed-predicted activity) were found to be minimal and are presented in Table 4:

\[ N_{\text{training}} = 26, N_{\text{test}} = 7, q^2 = 0.7359, q^2_{\text{se}} = 0.3562, F_{\text{test}} = 30.8743, \text{and} \quad \text{pred}_{\text{r}}^2 = 0.6743. \]

The 3D model using the SW-kNN-MFA analysis method \( q^2 \) was found to be 0.7359 which suggests that the model could be useful for predicting SGLT2 inhibitor for such thiophenyl derivatives. These points suggested the significance and requirement of electrostatic and steric and hydrophobic properties as mentioned in the ranges for structure-activity relationship and biological activity of thiophenyl analogues. It shows a positive contribution towards the activity, which indicates that H$_{1153}$ hydrophobic substitution at R position favors activity. Figure 1(i) showed the hydrophobic contour the presence of yellow contours covering the R positions of the ring indicating that hydrophobic substituents may be well tolerated in that region. The R position of the thiophenyl was surrounded by a yellow contour which also indicated that hydrophobic groups at this position may increase activity. Less bulky substituents are tolerated at thiophenyl ring meaning that increasing size of the groups substituted in these regions reduces SGLT2 inhibitory activity, since S$_{190}$ have negative values. Positive values for the hydrophobic l1153 lattice points around ring indicate that SGLT2 inhibitory activity could be increased by substituting more hydrophobic groups in these regions. Similarly, the positive values of electrostatic descriptors suggested the requirement of electropositive or sterically bulky groups at the position of generated data point E$_{1090}$ around thiophenyl pharmacophore for maximum activity. The electrostatic E$_{1090}$ data point generated which indicates sterically bulky groups such as benzene, methyl, ethyl, and isopropyl was required at R position. The graph for observed versus predicted activity for the series is plotted in Figure 1(j). The residuals (observed-predicted activity) were found to be minimal and are presented in Table 4.

4. Conclusions

QSAR study was performed on thiophenyl C-aryl glucoside derivatives for their SGLT2 inhibitors as potential antidiabetic agents. Genetic algorithms (GA), simulated annealing (SA), and stepwise (SW) forward-backward selection methods have been employed for selection of relevant descriptors. Comparison of the obtained results indicated the superiority of the genetic algorithm over the stepwise method for feature selection. 2D QSAR further revealed that a specific group or type of descriptor is not sufficient to capture the true factors responsible for the activity in the set of inhibitor compounds. This study also revealed that S$_{190}$, along with LUMO energy and SaaSE-index, forms a powerful tool to improve a QSAR model. This study used T$_{C,CL1}$ to investigate whether a similarity based set generation method would lead to better understanding of the QSAR models. The 2D and 3D QSAR suggested the presence of negative steric potential at R position in thiophenyl nucleus, that is, R position in thiophenyl nucleus should acquire less steric or less bulky substituents are favorable as well as according to models. The constructed 3D QSAR models and structure-activity relationship (SAR) analyses of the compounds used in the study suggested that an electronegative and bulky substituent at R position and one less bulky substituent at X, R position of thiophenyl analogs are required to design novel SGLT2 inhibitors. We emphasize in this study that the E$_{1153}$ electron-donating groups on the thiophenyl ring increase biological activity of compounds. Electron-withdrawing groups are highly favorable. Furthermore, the kNN-MFA maps offered enough information to understand the structure-activity relationship and identified structural features influencing the inhibitory activity. The correlation of the results obtained from 3D QSAR study successfully explored the primitive structure-activity relationship. The findings can be quite useful to aid the designing of novel antidiabetic agents with high predicted potent activity.

Conflict of Interests

The authors declare no conflict of interests.

Acknowledgments

The authors wish to express gratitude to V-life Science Technologies Pvt. Ltd. for providing the trial version software for the study. The authors thank the referees for their critical comments and for suggesting improvements.

References

[1] A. Ceriello, “Proactive study: (r)evolution in the therapy of diabetes?” Diabetic Medicine, vol. 22, no. 11, pp. 1463–1464, 2005.
[2] K. G. Alberti and P. Z. Zimmet, “Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation,” Diabetic Medicine, vol. 15, pp. 539–553, 1998.
[3] V. Beletate, R. P. El Dib, and A. N. Atallah, “Zinc supplementation for the prevention of type 2 diabetes mellitus,” Cochrane Database of Systematic Reviews, vol. 1, Article ID CD005525, 2007.
[4] T. Kuzuya, S. Nakagawa, J. Satoh et al., “Report of the Committee on the classification and diagnostic criteria of diabetes mellitus,” Diabetes Research and Clinical Practice, vol. 55, no. 1, pp. 65–85, 2002.
[5] T. Kuzuya and A. Matsuda, “Classification of diabetes on the basis of etiologies versus degree of insulin deficiency,” Diabetes Care, vol. 20, no. 2, pp. 219–220, 1997.
[6] D. Porte Jr., “Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications,” Diabetess/Metabolism Research and Reviews, vol. 17, pp. 181–188, 2001.
[7] W. Zhang, A. Welihinda, J. Mechanic et al., “EGT14,2 a potent and selective SGLT2 inhibitor, attenuates blood glucose and
HbA1c levels in db/db mice and prolongs the survival of stroke-prone rats," *Pharmacological Research*, vol. 63, no. 4, pp. 284–293, 2011.

[8] Y. Kanai, W. S. Lee, G. You, D. Brown, and M. A. Hediger, “The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal re-absorptive mechanism for D-glucose,” *The Journal of Clinical Investigation*, vol. 93, no. 1, pp. 397–404, 1994.

[9] O. Marsenic, “Glucose control by the kidney: an emerging target in diabetes,” *American Journal of Kidney Diseases*, vol. 53, no. 5, pp. 875–883, 2009.

[10] W. S. Lee, Y. Kanai, R. G. Wells, and M. A. Hediger, “The high affinity Na+/glucose cotransporter. Re-evaluation of function and distribution of expression,” *The Journal of Biological Chemistry*, vol. 269, no. 16, pp. 12032–12039, 1994.

[11] B. Mackenzie, M. Panayotova-Heiermann, D. D. Loo, J. E. Lever, and E. M. Wright, “SAA T1 is a low affinity Na+/glucose cotransporter and not an amino acid transporter. A reinterpretation,” *The Journal of Biological Chemistry*, vol. 269, pp. 22488–22491, 1994.

[12] E. M. Wright and E. Turk, “The sodium/glucose cotransport family SLC5,” *Pflügers Archiv*, vol. 447, no. 5, pp. 510–518, 2004.

[13] K. Katsuno, Y. Fujimori, Y. Takemura et al., “Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 320, no. 1, pp. 323–330, 2007.

[14] B. Mackenzie, D. D. Loo, M. Panayotova-Heiermann, and E. M. Wright, “Biophysical characteristics of the pig kidney Na+/glucose cotransporter SGLT2 reveal a common mechanism for SGLT1 and SGLT2,” *The Journal of Biological Chemistry*, vol. 271, no. 51, pp. 32678–32683, 1996.

[15] W. N. Washburn, “Development of the renal glucose reabsorption inhibition: a new mechanism for the pharmacotherapy of diabetes mellitus type 2,” *Journal of Medicinal Chemistry*, vol. 52, no. 7, pp. 1785–1794, 2009.

[16] G. Toggenburger, M. Kessler, and G. Semenza, “Phlorizin as a probe of the small-intestinal Na+-d-glucose cotransporter. A model,” *Biochimica et Biophysica Acta*, vol. 688, no. 2, pp. 557–571, 1982.

[17] A. Oku, K. Ueta, K. Arakawa et al., “Antihyperglycemic effect of T-1095 via inhibition of renal Na+-glucose cotransporters in streptozotocin-induced diabetic rats,” *Biological and Pharmaceutical Bulletin*, vol. 23, no. 12, pp. 1434–1437, 2000.

[18] Y. Fujimori, K. Katsuno, K. Ojima et al., “Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats,” *European Journal of Pharmacology*, vol. 609, no. 1–3, pp. 148–154, 2009.

[19] Y. Fujimori, K. Katsuno, I. Nakashima, Y. Ishikawa-Takemura, H. Fukuji, and M. Isaji, “Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 327, no. 1, pp. 268–276, 2008.

[20] L. Rossetti, D. Smith, G. I. Shulman, D. Papachristou, and R. A. DeFronzo, “Correction of hyperglycemia with phlorizin normalizes tissues sensitivity to insulin in diabetic rats,” *Journal of Clinical Investigation*, vol. 79, no. 5, pp. 1510–1515, 1987.

[21] S. Kar and K. Roy, “Predictive toxicology using QSAR: a perspective,” *Journal of the Indian Chemical Society*, vol. 87, no. 12, pp. 1455–1515, 2010.

[22] M. C. Sharma, D. V. Kohli, S. C. Chaturvedi, and S. Sharma, “Molecular modelling studies of some substituted 2-butylnizemidazo derivatives as angiotensin II receptor antagonists as antihypertensive agents,” *Digest Journal of Nanomaterials and Biоструктуры*, vol. 4, no. 4, pp. 843–856, 2009.

[23] M. C. Sharma, D. V. Kohli, N. K. Sahu, S. Sharma, and S. C. Chaturvedi, “2D-QSAR studies of some 1, 3, 4-thiadiazole-2-yl azetidine 2-one as antimicrobial activity,” *Digest Journal of Nanomaterials and Biоструктуры*, vol. 4, no. 2, pp. 339–347, 2009.

[24] M. C. Sharma, D. V. Kohli, S. Sharma, and S. C. Chaturvedi, “Two dimensional-quantitative structure activity relationships -2, 3 diarylthiophenes as selective cox-1/2 inhibitors,” *Digest Journal of Nanomaterials and Biоструктуры*, vol. 4, no. 3, pp. 459–469, 2009.

[25] A. Dhakad, M. C. Sharma, S. C. Chaturvedi, and S. Sharma, “3D-QSAR studies, biological evaluation studies on some substituted 3-Chloro-1-[5-(5-Chloro-2-phenyl-benzimidazole-1-ylmethyl)-[1, 3, 4] thiadiazole-2-yl]-azetidin-2-one as potential antimicrobial activity,” *Digest Journal of Nanomaterials and Biоструктуры*, vol. 4, no. 2, pp. 275–284, 2009.

[26] M. C. Sharma, D. V. Kohli, N. K. Sahu, S. Sharma, and S. C. Chaturvedi, “QSAR, synthesis and biological activity studies of some thiazolidinones derivatives,” *Digest Journal of Nanomaterials and Biоструктуры*, vol. 4, no. 1, pp. 223–232, 2009.

[27] M. C. Sharma, S. Sharma, P. Sharma, and A. Kumar, “Study of physiochemical properties-inducible nitric oxide synthase relationship of substituted quinazolinamines analogs: pharmacophore identification and QSAR studies,” *Arabian Journal of Chemistry*, 2013.

[28] M. C. Sharma and D. V. Kohli, “An approach to design antihypertensive agents by 2D QSAR studies on series of substituted benzimidazoles derivatives as angiotensin II receptor antagonists,” *Arabian Journal of Chemistry*, 2011.

[29] M. C. Sharma and D. V. Kohli, “QSAR analysis and 3D QSAR kNNMFA approach on a series of substituted quinolines derivatives as angiotensin II receptor antagonists,” *Arabian Journal of Chemistry*, 2011.

[30] M. C. Sharma and D. V. Kohli, “QSAR studies on substituted benzimidazoles as angiotensin II receptor antagonists: kNN-MFA approach,” *Arabian Journal of Chemistry*, 2011.

[31] M. C. Sharma and D. V. Kohli, “Two dimensional and k-Nearest neighbor molecular field analysis approach on substituted triazolone derivatives: an insight into the structural requirement for the angiotensin II receptor antagonist,” *Journal of Saudi Chemical Society*, 2011.

[32] M. C. Sharma and D. V. Kohli, “QSAR analysis of imidazo [4,5-b] pyridine substituted a-phenoxophenylacetic acids as angiotensin II AT1 receptor antagonists,” *Journal of Saudi Chemical Society*, 2011.

[33] M. C. Sharma and D. V. Kohli, “Predicting substituted 2-butylnizemidazo derivatives as angiotensin II receptor antagonists: 3D-QSAR and pharmacophore modeling,” *Journal of Saudi Chemical Society*, 2011.

[34] M. C. Sharma and D. V. Kohli, “3D QSAR studies of some substituted imidazolines derivatives angiotensin II receptor antagonists,” *World Applied Sciences Journal*, vol. 12, no. 11, pp. 2129–2134, 2011.

[35] M. C. Sharma and D. V. Kohli, “Exploration of quantitative structure activity relationship studies on a series of substituted
M. C. Sharma and D. V. Kohli, “Predicting 2,3-Dihydro-quinazolinones as angiotensin II AT1 receptor antagonists,” World Applied Sciences Journal, vol. 12, no. 11, pp. 211–219, 2011.

[36] M. C. Sharma and D. V. Kohli, “3D QSAR kNNMFA approach studies on series of substituted piperidin-2-one biphenyl tetrazoles as angiotensin II receptor antagonists,” American-Eurasian Journal of Toxicological Sciences, vol. 3, pp. 75–84, 2011.

[37] M. C. Sharma and D. V. Kohli, “3D QSAR approach on substituted isoxazolidines derivatives as angiotensin II receptor antagonists,” American-Eurasian Journal of Toxicological Sciences, vol. 3, no. 2, pp. 85–91, 2011.

[38] M. C. Sharma and D. V. Kohli, “2D- and 3D- QSAR studies of substituted 4H-pyrido [1, 2-a] pyrimidin-4-ones angiotensin II receptor antagonists,” European Journal of Toxicological Sciences, vol. 3, pp. 92–100, 2011.

[39] M. C. Sharma, “Structural insight for (6-oxo-3-pyridazinyl)-benzimidazoles derivatives as angiotensin II receptor antagonists: QSAR, pharmacophore identification and kNNMFA approach,” Journal of Saudi Chemical Society, 2012.

[40] M. C. Sharma and D. V. Kohli, “A comprehensive structure-activity analysis of 5-Carboxyl Imidazolyl biphenyl Sulfonylureas derivatives: angiotensin AT1 receptor antagonists: 2D- and 3D-QSAR approach,” Arabian Journal of Chemistry, 2012.

[41] M. C. Sharma and D. V. Kohli, “Comprehensive structure-activity relationship analysis of isoxazolinyl and isoxazolidinyl substituted quinazolinone derivatives as angiotensin II receptor antagonists,” Journal of Saudi Chemical Society, 2012.

[42] M. C. Sharma and D. V. Kohli, “QSAR analysis of 2-alkyl-4-(biphenylmethoxy) quinolines as angiotensin II receptor antagonists,” Oxidation Communications, vol. 35, no. 4, pp. 928–944, 2012.

[43] M. C. Sharma and D. V. Kohli, “Insight into the structural requirement of arytriazolinone derivatives as angiotensin II AT1 receptor: 2D and 3D-QSAR k-nearest neighbor molecular field analysis approach,” Medicinal Chemistry Research, vol. 21, no. 10, pp. 2837–2853, 2012.

[44] M. C. Sharma and D. V. Kohli, “Predicting 2,3-Dihydro-quinazolinones derivatives as angiotensin II receptor antagonists: 2D QSAR approach,” Oxidation Communications, vol. 35, no. 3, pp. 722–734, 2012.

[45] M. C. Sharma, S. Sharma, and D. V. Kohli, “QSAR approach insight the structural requirement of substituted quinazoliones derivatives as angiotensin ii receptor antagonists,” Oxidation Communications, vol. 35, no. 3, pp. 694–707, 2012.

[46] M. C. Sharma, S. Sharma, and D. V. Kohli, “Qsar studies of 2-alkylbenzimidazole derivatives as angiotensin ii receptor antagonists,” Oxidation Communications, vol. 35, no. 3, pp. 708–721, 2012.

[47] M. C. Sharma, S. Sharma, and K. S. Bhadoriya, “QSAR analyses and pharmacophore studies of tetrazole and sulfonamide analogs of imidazo[4,5-b]pyridine using simulated annealing based feature selection,” Journal of Saudi Chemical Society, 2012.

[48] M. C. Sharma and D. V. Kohli, “Rationalization of 2-alkyl-benzimidazoles bearing a N-phenyl pyrrole moiety as novel Angiotensin II AT1 receptor antagonists—a QSAR approach,” Oxidation Communications, vol. 36, no. 1, pp. 190–204, 2013.

[49] M. C. Sharma and D. V. Kohli, “Quantitative structure-activity relationship analysis of series of substituted piperidin-2-one biphenyl tetrazoles analogues as novel angiotensin ii receptor antagonists,” Oxidation Communications, vol. 36, no. 1, pp. 176–189, 2013.

[50] M. C. Sharma and D. V. Kohli, “A comprehensive structure-activity analysis 2,3,5-trisubstituted 4,5-dihydro-4-oxo-3H-imidazo [4,5-c] pyridine derivatives as angiotensin II receptor antagonists: using 2D- and 3D-QSAR approach,” Medicinal Chemistry Research, vol. 22, no. 2, pp. 588–605, 2013.

[51] M. C. Sharma and D. V. Kohli, “Comprehensive two and three-dimensional QSAR studies of 3-substituted 6-butyl-1,2dihydropyridin-2-ones derivatives as angiotensin II receptor antagonists,” Medicinal Chemistry Research, vol. 22, no. 3, pp. 1107–1123, 2013.

[52] M. C. Sharma, “Structural requirements of some 2-(1-propyl-piperidin-4-yl)-1H-benzimidazole-4-carboxamide derivatives as poly (ADP-ribose) polymerase (PARP) for the treatment of cancer: QSAR approach,” Interdisciplinary Sciences: Computational Life Sciences, 2014.

[53] M. C. Sharma, S. Sharma, N. K. Sahu, and D. V. Kohli, “QSAR studies of some substituted imidazolinones angiotensin II receptor antagonists using Partial Least Squares Regression (PLSR) method based feature selection,” Journal of Saudi Chemical Society, vol. 17, no. 2, pp. 219–225, 2013.

[54] M. C. Sharma, “Discovery of potent antihypertensive ligands substituted imidazolyl biphenyl sulfonyleuca analogs as angiotensin II AT1 receptor antagonists by molecular modelling studies,” Interdisciplinary Sciences: Computational Life Sciences, 2014.

[55] M. C. Sharma, D. V. Kohli, and S. Sharma, “Molecular modeling studies of substituted 2,4,5-trisubstituted triazolinones aryl and nonaryl derivatives as angiotensin II AT1 receptor antagonists,” Journal of Chemistry, vol. 2013, Article ID 427181, 14 pages, 2013.

[56] M. C. Sharma, “Discovery of new lead pyrimidines derivatives as potential cannabionoid CB1 receptor antagonist through molecular modeling and pharmacophore approach,” Medicinal Chemistry Research, vol. 23, no. 5, pp. 2287–2311, 2014.

[57] M. C. Sharma, “Comparative pharmacophore modeling and QSAR studies for structural requirements of some substituted 2-aminoypyridines derivatives as inhibitors nitric oxide synthases,” Interdisciplinary Sciences: Computational Life Sciences, 2014.

[58] M. C. Sharma, “A structure-activity relationship study of imidazo[5,5-carboxylic acids derivatives as angiotensin II receptor antagonists combining 2D and 3D QSAR methods,” Interdisciplinary Sciences: Computational Life Sciences, 2014.

[59] M. C. Sharma, S. Sharma, P. Sharma, A. Kumar, and K. S. Bhadoriya, “Structural insights for substituted acyl sulfonamides and acyl sulfamides derivatives of imidazole as angiotensin II receptor antagonists using molecular modeling approach,” Journal of the Taiwan Institute of Chemical Engineers, vol. 45, no. 1, pp. 12–23, 2014.

[60] M. C. Sharma, “Molecular modelling studies for the discovery of new substituted pyridines derivatives with angiotensin II AT1 receptor antagonists,” Interdisciplinary Sciences, Computational Life Sciences, vol. 6, no. 3, pp. 197–207, 2014.

[61] M. C. Sharma, S. Sharma, N. K. Sahu, and D. V. Kohli, “3D QSAR kNN-MFA studies on 6-substituted benzimidazoles derivatives as nonpeptide angiotensin II receptor antagonists: a rational approach to antihypertensive agents,” Journal of Saudi Chemical Society, vol. 17, no. 2, pp. 167–176, 2013.

[62] M. C. Sharma, “Prospective QSAR-based prediction models with pharmacophore studies of oxadazole-substituted α-isoproxy phenylpropanoic acids on with dual activators of PPARγ and PPARα,” Interdisciplinary Sciences: Computational Life Sciences, 2014.
M. C. Sharma, S. Sharma, P. Sharma, and A. Kumar, “Pharmacophore and QSAR modeling of some structurally diverse azaaurones derivatives as anti-malarial activity,” *Medicinal Chemistry Research*, vol. 23, no. 1, pp. 181–198, 2014.

M. C. Sharma, “Rationalization of physicochemical characters and pharmacophore approach of 3-(4-biphenylmethyl) 4, 5-dihydro-4-oxo-3H-imidazo [4, 5-c] pyridines analogs toward angiotensin II AT receptor antagonists,” *Interdisciplinary Sciences: Computational Life Sciences*. In press.

M. C. Sharma, “Molecular modeling studies of substituted 3,4-dihydroxychalcone derivatives as 5-lipoxygenase and cyclooxygenase inhibitors,” *Medicinal Chemistry Research*, vol. 23, no. 4, pp. 1797–1818, 2014.

M. C. Sharma, “A structure-activity relationship study of naphthoquinone derivatives as antitubercular agents using molecular modelling techniques,” *Interdisciplinary Sciences: Computational Life Sciences*. In press.

M. C. Sharma, “Identification of 3-nitro-2, 4, 6-trihydroxybenzamide derivatives as photosynthetic electron transport inhibitors by QSAR and pharmacophore studies,” *Interdisciplinary Sciences: Computational Life Sciences*, 2014.

S. H. Lee, K. S. Song, J. Y. Kim et al., “Novel thiophenyl C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents,” *Bioorganic and Medicinal Chemistry*, vol. 19, no. 19, pp. 5813–5832, 2011.

VLife MDS 3.5, *Molecular Design Suite*, Vlife Sciences Technologies Pvt. Ltd., Pune, India, 2008, [http://www.vlifesciences.com](http://www.vlifesciences.com/).

T. A. Halgren, “Merck molecular force field. III. Molecular geometries and vibrational frequencies for MMFF94,” *Journal of Computational Chemistry*, vol. 17, no. 5–6, pp. 553–586, 1996.

A. Golbraikh and A. Tropsha, “Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection,” *Journal of Computer-Aided Molecular Design*, vol. 16, no. 5–6, pp. 357–369, 2002.

S. Ajmani, K. Jadhav, and S. A. Kulkarni, “Three-dimensional QSAR using the k-nearest neighbor method and its interpretation,” *Journal of Chemical Information and Modeling*, vol. 46, no. 1, pp. 24–31, 2006.

R. D. Cramer III, D. E. Patterson, and J. D. Bunce, “Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins,” *Journal of the American Chemical Society*, vol. 110, no. 18, pp. 5959–5967, 1988.